A discussion of the progress of the DEWS II TFOS report particularly with a view on what has changed in practice and what more can be derived from the report.
Sponsored by an educational grant from Scope Ophthalmics.
Baudouin C, Aragona P, Van Setten G, et al; ODISSEY European Consensus Group members. Diagnosing the severity of dry eye: a clear and practical algorithm. Br J Ophthalmol. 2014;98(9):1168-1176.
Baudouin C, Messmer EM, Aragona P, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100(3):300-306.
Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438-510.
Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification Report. Ocul Surf. 2017;15:276-283.
Dohlman TH, Ciralsky JB, Lai EC.Tear film assessments for the diagnosis of dry eye. Curr Opin Allergy Clin Immunol.2016;16(5):487-491.
Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II iatrogenic report. Ocul Surf. 2017;15(3):511-538.
Jones L, Downie DE, Donald Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575-628.
Lemp M, Crews L, Bro A, et al. Distribution of Aqueous-Deficient and Evaporative Dry Eye in a Clinic-Based Patient Cohort: A Retrospective Study Cornea. 2012; 31(5):472-478.
Majmudar PA. CEDARS Dry Eye Algorithm. Ophthalmology Management. https://www.ophthalmologymanagement.com/newsletters/ocular-surface-news-for-mds/february-27,-2019. Updated Feb. 27, 2019. Accessed February 25, 2020.
Millán A, Eloy V, Gude F et al; Incidence and risk factors of dry eye in a Spanish adult population: 11-year follow-up from the Salnés Eye Study. Cornea. 2018;37(12):1527-1534.
Nichols KK, Foulks GN, Bron AJ, et al. The International Workshop on Meibomian Gland Dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52(4):1922-1929.
Ong ES, Felix ER, Levitt RC, Feuer WJ, et al. Epidemiology of discordance between symptoms and signs of dry eye. Br J Ophthalmol. 2018;102(5):674-679.
Pult H, Wolffsohn JS. The development and evaluation of the new Ocular Surface Disease Index-6. Ocul Surf. 2019;17(4):817-821.
Sheppard AL, Wolffsohn JS. Digital eye strain: prevalence, measurement and amelioration. BMJ Open Ophthalmol. 2018;3(1):e000146.
Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15(3):334-365.
Sullivan BD, Whitmer D, Nichols KK, et al. An objective approach to dry eye disease severity. Invest Ophthal Vis Sci. 2010;51(12):6125-6130.
Sutu C, Fukuoka H, Afshar N. Mechanisms and management of dry eye in cataract surgery patients. Curr Opin Ophthalmol. 2016;27(1):24–30.
Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15; 539-574.
Credit Designation Statement
Evolve Medical Education LLC designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Evolve is an approved COPE Administrator.
This course is COPE approved for 1.0 hour of CE credit for optometrists.
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Arthur Cummings MD, and or spouse, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Scope Ophthalmics, Tearclear, Wavelight, and Vivior. Grant Research Support: Alcon, Allotex, and RXSight. Speaker’s Bureau: Alcon, TearLab, Wavelight, and Vivior. Share/Stockholder: Alcon, and Novartis.
Charles Flowers, MD, and or spouse, has had no affiliations with commercial interests.
Professor James Wolffsohn and or spouse, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, plc., Bausch + Lomb, Coopervision, Nevakar, Novartis, and RB. Grant Research Support: Allergan, Johnson & Johnson, Rayner, Innovate, U.K. Share/Stockholder: Eyoto.
Marguerite McDonald and or spouse, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, plc., Bausch + Lomb, Johnson & Johnson Vision, Ocusoft, and Scope Ophthalmics.
Editorial Support Disclosures:
Erin K. Fletcher, MIT, director of compliance and education, Cassandra Richards, director of education development, Evolve, has no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or Scope Ophthalmic.